MoonLake's Autoimmune Drug Failure Causes Stock Collapse

MoonLake Immunotherapeutics reported failure in its Phase 3 trials for the autoimmune skin condition hidradenitis suppurativa, leading to a sharp decline in its stock price. Despite some statistical significance in one study, the drug sonelokimab did not meet the efficacy benchmarks required to compete with existing treatments, casting doubt on its commercial prospects.